Enliven Therapeutics, Inc.
ELVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001672619
In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 217 institutions reported holding it in 13F filings for Q3 2026, worth $3.79B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 20, 2026
- $3.42B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.82M in total
- 6
- 13F holdersQ3 2026, +7 vs. previous quarter
- 217
- 13F valueReported value at the end of Q3 2026
- $3.79B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$103.7M
- No comparable prior period
- Free cash flow, FY2025
- -$70.5M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.3M
- Shares sold short
- Change
- +962.4K
- +10.3% vs. previous
- Days to cover
- 5.69
- At average daily volume
Superinvestors holding ELVN, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding ELVN at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Enliven Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2026 (view filing)5:07 PM ET | Nov 17 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $46.84 | −$234.2K | −16.7%25.0K after | 2 lots10b5-1 |
| Oct 21, 2026 (view filing)5:53 PM ET | Oct 19 | 2 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $38.48 | −$231.5K | −13.7%38.0K after | 10b5-1 |
| Oct 21, 2026 (view filing)5:51 PM ET | Oct 19 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $38.47 | −$192.3K | −16.7%25.0K after | 10b5-1 |
| Oct 5, 2026 (view filing)4:57 PM ET | Oct 1 | 4 days | Garland J. ScottDirector | SSale | −13.0K | $46.67 | −$606.7K | −100.0%0 after | |
| Sep 21, 2026 (view filing)5:23 PM ET | Sep 17 | 4 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $50.35 | −$303.0K | −13.7%38.0K after | 3 lots10b5-1 |
| Sep 21, 2026 (view filing)5:22 PM ET | Sep 17 | 4 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $50.35 | −$251.8K | −16.7%25.0K after | 3 lots10b5-1 |
| Aug 19, 2026 (view filing)4:17 PM ET | Aug 17 | 2 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $58.58 | −$352.6K | −13.1%40.0K after | 2 lots10b5-1 |
| Aug 19, 2026 (view filing)4:16 PM ET | Aug 17 | 2 days | Collins Helen LouiseCHIEF MEDICAL OFFICER | SSale | −5.00K | $58.59 | −$292.9K | −16.7%25.0K after | 2 lots10b5-1 |
| Aug 6, 2026 (view filing)8:18 PM ET | Aug 4 | 2 days | Derynck Mika KDirector | SSale | −158.8K | $60.21 | −$9.56M | −100.0%0 after | 10b5-1 |
| Jul 21, 2026 (view filing)5:24 PM ET | Jul 17 | 4 days | Hohl BenjaminCHIEF FINANCIAL OFFICER | SSale | −6.02K | $52.64 | −$316.8K | −11.6%46.1K after | 5 lots10b5-1 |
Top 10 13F holders, Q3 2026
See all 217 holdersThe largest institutional positions in Enliven Therapeutics, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 10,827,727 | $496.3M | 0.02% | +802,710+8.0% | Added |
| OrbiMed Advisors LLC | 6,776,632 | $310.6M | 5.70% | 00.0% | Unchanged |
| Polar Capital Holdings Plc | 6,425,271 | $294.5M | 0.82% | −5,365−0.1% | Reduced |
| BlackRock, Inc. | 5,711,966 | $261.8M | 0.00% | +1,352,262+31.0% | Added |
| Commodore Capital LP | 3,275,000 | $150.1M | 11.63% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 3,225,000 | $147.8M | 3.82% | −775,000−19.4% | Reduced |
| Vanguard Capital Management LLC | 2,893,109 | $132.6M | 0.00% | +324,107+12.6% | Added |
| Price T Rowe Associates Inc | 2,350,207 | $107.7M | 0.01% | −553,700−19.1% | Reduced |
| Fairmount Funds Management LLC | 1,855,644 | $85.1M | 5.33% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 1,708,920 | $78.4M | 0.00% | +301,718+21.4% | Added |
Holders of 5% or more of ELVN
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Enliven Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%10.7M shares | +1.70 ppfrom 13.30% | Feb 8, 20218 filings | Aug 6, 2026 | SEC |
| OrbiMed Advisors LLC | 13D/A | 9.50%6.77M shares | −1.43 ppfrom 10.93% | Feb 28, 20236 filings | Jun 24, 2026 | SEC |
| Polar Capital Holdings Plc | 13G/A | 8.46%5.06M shares | 0.00 ppfrom 8.46% | Nov 13, 20246 filings | Jun 22, 2026 | SEC |
| Commodore Capital LP | 13G/A | 7.70%4.80M shares | −2.20 ppfrom 9.90% | Oct 24, 20229 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.10%5.21M shares | +2.00 ppfrom 5.10% | Oct 24, 20244 filings | Oct 27, 2026 | SEC |